Please assess the completion status of the following clinical trial:

Trial Title: uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic castration resistant prostate cancer~* Approved to receive Radium-223 therapy~* Written and oral consent~Exclusion Criteria:~* Lack of communication skills~* Other known malignant disease~* Known allergy towards IMP~* Severe claustrophobia~* If a participant exhibits allergic reaction i the IMP, the participant will be excluded from further participation in the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- uPAR PET/CT (Type: EXPERIMENTAL): Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).